The combination of genomic profiling and high-tech targeted drug delivery is opening up a new front in the fight against cancer.
Could cell-based synthetic circuits make pills and ointments a thing of the past for chronic disease?
Holding back the “guardian of the genome” opens the gates to more efficient transdifferentiation
Send me the latest from The Translational Scientist.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.